{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 40,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 20,
  "notes": "Includes a footnote explaining changes in reporting for specific drugs (Koselugo, Andexxa).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/6",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Growth across disease areas - Total Revenue ($m)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78b324ac-3fdc-4536-aaf8-fc0dd898d930",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Growth across geographies - Total Revenue ($m)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e4c509e-225e-4642-9e00-6a6424c54e2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.32,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Q1 2022 | % Disease Area",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "323785e2-99f2-4a02-acae-aac80cd3665c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.82,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Q1 2022 | % Geography",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "459df597-74e4-4d7e-aaf9-5614de28e259",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Total revenue at actual exchange rates; changes at CER. R&I = Respiratory & Immunology; CVRM = Cardiovascular, Renal & Metabolism; V&I = Vaccines & Immune Therapies; US = United States; ERoW = Established Rest of World; Koselugo is now reported in Rare Disease, and Andexxa is now reported in the CVRM disease area. In previous results announcements, Koselugo was included in the Oncology disease area and Andexxa was included in Rare Disease.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e53a186-01e7-4e7a-a386-f2e4619452c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Performance benefits from disease area and geographic breadth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "848c5302-866a-4336-adb3-f5a9c0097347",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Q1 2022 Total Revenue performance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90ecf2be-730b-4348-a74e-5b235bb83fb3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "b213f952-f7c0-4403-889c-b9a0f8fafa05",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The slides highlight the company's strong top-line growth and variability between quarters",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "633b67bb-9ede-479d-8827-edd694513a87",
      "evidence": "The slides provide KPI overviews and key messages",
      "position": 0,
      "objective": "Highlighting strong top-line growth",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}